Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674118 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL24439068 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL29674209 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL24439064 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL19533902 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL7537535 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL8884810 | 0.77 | ALDH1A1 (0.39) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL4561370 | 0.77 | ALDH1A1 (0.39) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL20103023 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL3839504 | 0.75 | SLC18A3 (0.44) | ALDH1A1CHRM2OPRM1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001946-B1 | QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1687642-B1 | Screening methods for combinations of biological compounds | CENTELION (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6482834-B2 | ANTIPROLIFERATION AGENTS; ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-09-20 | — | — | US | disclosed |
| EP-1133481-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| WO-2000031049-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | ALDH1A1 3361/4885CHRM2 4021/4885OPRM1 2658/4885 |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | ALDH1A1 4598/4885CHRM2 2898/4885OPRM1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.